Omeprazol Sandoz (Omeprazole)

Omeprazole irreversibly inhibits the H⁺/K⁺‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By blocking this final step of acid secretion, it markedly reduces both basal and stimulated gastric acid output, raising gastric pH and allowing ulcer healing and symptom control.

The specific dose and infusion rate of Omeprazol Sandoz are determined by the prescribing clinician based on the patient’s condition, severity, and renal or hepatic function. The product is supplied as an injectable solution for intravenous administration, and dosing instructions are provided on the prescription label.

Safety of intravenous omeprazole during pregnancy or lactation has not been fully established. The decision to use the product should be based on a careful assessment of the potential benefits versus any possible risks to the fetus or infant, and it should be prescribed only when clearly needed.

To request Omeprazol Sandoz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including cold‑chain handling) and any required import documentation.

Omeprazol Sandoz provides the same mechanism of action as other PPIs such as pantoprazole or esomeprazole but is formulated for intravenous use, allowing rapid onset in patients who cannot take oral medication. While oral PPIs are convenient for chronic therapy, the injectable form is preferred in acute care settings, critical care, or when oral absorption may be compromised.

Omeprazol Sandoz must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product reaches room temperature for a short period during preparation, it may be used immediately, but any remaining solution should be discarded.

The product is given by intravenous infusion. The prescribed dose is diluted in an appropriate compatible IV fluid and administered over the recommended infusion time, typically 30‑60 minutes, under clinical supervision. Monitoring of vital signs and patient response is advised during and after the infusion.

Serious adverse events include anaphylactic or severe allergic reactions, Clostridioides difficile‑associated colitis, significant liver enzyme elevations indicating hepatotoxicity, severe hypomagnesemia that can cause cardiac arrhythmias, and rare cases of Stevens‑Johnson syndrome. Prompt medical attention is required if any of these symptoms develop.

Patients with known hypersensitivity to omeprazole or any component of the injectable formulation should avoid its use. Caution is also advised for individuals with severe hepatic impairment, those receiving concomitant drugs that rely on gastric acidity for absorption (e.g., atazanavir), and patients with a history of severe allergic reactions to proton pump inhibitors.